Clinical Trial Update: Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase II clinical trial investigating individualized immunotherapy for early-stage unfavorable classical Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Snippet

Sponsor: University of Cologne | Conditions: Classical Hodgkin Lymphoma | Phase 2 | Status: RECRUITING